News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Combination therapy for glioblastoma shows promising results in early-stage research

Al's Comment:

 This project is funded, in part, by the Musella Foundation!

It shows that that the vaccine can be enhanced significantly by using other immune modulating drugs.  The  full text of the article is not available for free, only the abstract is free.  The full text shows how strong the effect is when using each treatment separately, then in all combinations.  It is a major improvement.

This project also shows, I think for the first time, that the immune suppression caused by PD-L1 is created by tumor-infiltrating myeloid cells and not directly by the tumor cells, which is what I always assumed.  The huge significance of this is that doing a biopsy of a tumor  and testing for PD-L1 on the tumor cells shouldn't make any difference to how the treatment would work.  

I would love to see this being done in humans.


Posted on: 01/25/2017

 

Combination therapy for glioblastoma shows promising results in early-stage research

 

http://newsroom.ucla.edu/releases/combination-therapy-for-glioblastoma-shows-promising-results-in-early-stage-research

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740